News Sentiment

NUZ sentiment intelligence

Neurizon Therapeutics Limited news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 27 relevant articles
Exchange ASX Australia
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.07 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

87/100 classification confidence.

Company focus 27

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-4.3% over one week, +3.1% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

What Does Faster Trial Enrolment Mean for Neurizon Therapeutics (ASX:NUZ)?

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 87/100 classification
One-week reaction -4.3% Price reacting lower
Trend fit Trend inactive 3.1% over four weeks
Fair value -53.5% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 0
Neutral 27
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 27
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Kalkine 8
The Australian 3
Stockhead 3
Kalkine Media 2
smallcaps.com.au 2
Stock Titan 1
grafa.com 1
The Globe and Mail 1

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 2
Deals and strategy 2
Macro sensitivity 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-27 of 27